

- Flea(s)  
 bites, 2750  
 cat, 1078, 2750  
 dog, 2750  
 in endemic typhus. *See* Endemic (murine) typhus  
 in plague, 261e-4  
 Flea-borne spotted fever, 1155t  
 Flecainide  
 action of, 273e-6t  
 adverse effects of, 1480t, 1489  
 for arrhythmias, 1480t  
 for atrial fibrillation, 1489  
 for AV nodal reentry tachycardia, 1480  
 dosage of, 1480t  
 for focal atrial tachycardia, 1479  
 metabolism of, 34t  
 pharmacology of, 1480t  
 therapeutic monitoring of, 2765t  
 for ventricular arrhythmias, 1498  
 Flesh fly, 2747  
 Flexible sigmoidoscopy. *See* Sigmoidoscopy  
*FLI1* gene mutations, 101e-3t, 119e-4  
 Flinders Island spotted fever, 1157  
*FLNC* gene mutations, 135e-1  
 Floaters, 204  
 Floppy-valve syndrome. *See* Mitral valve prolapse  
 Flow limit, of lung, 306e-2  
 Flow-volume loop, 306e-3f, 306e-6, 1675, 1675f  
 Floxuridine, 2023  
*FLT3-ITD* gene mutations, 679, 680, 680t, 685  
*FLT3-KTD* mutation, 680t  
 Fluclxacillin, 822t, 937, 2023  
 Fluconazole  
 advantages of, 1330  
 adverse effects of, 246e-3t, 727t, 1330  
 for *Blastomyces* infections, 1338, 1339t  
 for *Candida* infections, 233  
 disseminated, 1344t  
 endocarditis, 1345  
 esophagitis, 1344t, 1910  
 liver abscess, 851  
 thrush, 233, 487  
 urinary tract, 868  
 vulvovaginal, 873t, 875, 1332, 1344t  
 for *Coccidioides* infections, 899, 1336  
 for *Cryptococcus* infections, 899, 1264, 1341  
 for cutaneous leishmaniasis, 1393  
 drug interactions of, 34t, 246e-3t  
 for febrile neutropenia, 491  
 indications for, 1330  
 for *Malassezia* infections, 1357  
 in pregnancy and lactation, 246e-3t  
 prophylactic use  
 for *Candida* infections, 1345  
 for *Cryptococcus* infections, 1341  
 for fungal infections, 1330  
 in HIV infection, 1252–1253t  
 in transplant recipients, 139e-4, 139e-4t  
 susceptibility testing for, 150e-8  
 for tinea versicolor, 350  
 Flucytosine  
 action of, 1331  
 adverse effects of, 417, 1331  
 for *Candida* endocarditis, 824  
 for *Candida* endophthalmitis, 1345  
 for cryptococcal meningitis, 1264, 1331, 1341  
 for *Cryptococcus* infections, 899  
 indications for, 1331  
 susceptibility testing for, 150e-8  
 Fludarabine  
 action of, 103e-14  
 adverse effects of, 103e-11t, 103e-14, 103e-25, 488, 607, 607t  
 for CLL, 703  
 in HSCT preparation, 139e-2  
 for Waldenström's macroglobulinemia, 718  
 Fluidocortisone  
 for adrenal insufficiency, 2326  
 for orthostatic hypotension, 146, 2617, 2644  
 for postural orthostatic tachycardia syndrome, 1477  
 for SIADH, 2282  
 for syncope, 145  
 Fluidocortisone suppression test, 2319  
 Fluid-attenuated inversion recovery (FLAIR) MRI  
 in brain tumors, 440e-9f, 598, 600f  
 characteristics of, 440e-4  
 in Hashimoto's encephalopathy, 441e-29f  
 in Huntington's disease, 441e-23f, 2622f  
 in lacunar infarction, 441e-17f  
 in limbic encephalitis, 441e-1f  
 in multiple sclerosis, 441e-27f, 441e-35f  
 in neurofibromatosis type 1, 441e-36f  
 in seizures, 2550  
 in viral encephalitis, 888, 895, 895f, 895t  
 Fluid requirements, 95e-1, 98e-4  
 Fluid restriction, 98e-4, 1739  
 Fluid retention, 98e-4, 98e-7, 138e-5  
 Fluid therapy  
 for alcoholic ketoacidosis, 319  
 for constipation, 61  
 for diabetic ketoacidosis, 318  
 for diarrhea, 267  
 for DKA, 2419  
 for HHS, 2420  
 for hypercalcemia, 314, 2480t  
 for hypovolemia, 298  
 for hypovolemic shock, 1749  
 for prevention of contrast-induced nephropathy, 1461  
 for sepsis/septic shock, 1757  
 Flukes. *See* Trematodes/trematode infections  
 Flumazenil, in opiate overdose management, 468e-3  
 Flunarizine  
 adverse effects of, 2594t, 2611  
 for hypnic headache, 2598  
 for migraine prevention, 2593, 2594t  
 Flunitrazepam, 469e-5, 473e-10t  
 Fluorescence in situ hybridization (FISH)  
 interphase, 83e-2, 83e-2f, 83e-3t  
 metaphase, 83e-2, 83e-2f, 83e-3t  
 for mutational analyses, 444  
 probes for, 83e-2  
 Fluorescent auramine microscopy, 245e-1  
 Fluorescent treponemal antibody-absorbed (FTA-ABS) test, 1137, 1137f  
 Fluoridation, 236  
 Fluoride  
 deficiency of, 96e-9t  
 functions of, 96e-10  
 for osteoporosis management/prevention, 2503  
 recommended intake of, 95e-3t  
 tolerable upper intake level of, 96e-9t  
 toxicity of, 96e-9t, 96e-10, 310  
 Fluorochrome stains, 150e-2  
 Fluorocytosine, 431e-6  
 Fluoroxyuridine, 431e-6  
 Fluoroquinolones  
 absorption of, 205e-6  
 action of, 931t, 932–933, 943  
 adverse effects of, 205e-6, 867, 867t, 938t, 943  
 onycholysis, 380  
 photosensitivity, 379, 389t  
 vesicles/bullae, 361  
 for anaerobic bacterial infections, 1101  
 for bite-wound infections, 167e-2  
 for *C. trachomatis* infections, 1171  
 for cystitis, 867, 867t  
 drug interactions of, 939t  
 empirical uses of, 767t  
 for *Enterobacter* infections, 1034  
 for gram-negative bacterial infections, 183e-2t  
 indications for, 943  
 for *M. pneumoniae* infections, 1164  
 in pregnancy and lactation, 937t  
 prophylactic, 945t  
 for pyelonephritis, 867  
 resistance to  
 in anaerobic bacteria, 1101  
 in *Campylobacter* spp., 1061  
 detection of, 773, 807  
 in *E. coli*, 1029  
 in gram-negative bacteria, 1027  
 in *Klebsiella* spp., 1033  
 mechanisms of, 931t, 943  
 in mycobacteria, 205e-6, 1118  
 in *Proteus* spp., 1033  
 in *Shigella*, 1057  
 in *V. cholera*, 1064  
 for TB, 205e-6  
 Fluoroscopy, in dysphagia, 256  
 Fluorosis, 96e-10  
 5-Fluorouracil (5-FU)  
 action of, 103e-14  
 adverse effects of, 103e-11t, 103e-14, 389t  
 cardiotoxicity, 1563  
 cutaneous, 361, 380  
 diarrhea, 103e-25  
 gastrointestinal, 1798  
 nail disorders, 380  
 nausea and vomiting, 103e-25  
 neurologic, 607t, 1793  
 for basal cell carcinoma, 502  
 for breast cancer, 530  
 for colorectal cancer, 543  
 drug interactions of, 103e-11t  
 for gastric cancer, 535  
 for gastrinoma, 2337  
 genetic variations in response to, 39t  
 for head and neck cancer, 505  
 for insulinoma, 2338  
 for pancreatic cancer, 556t, 557  
 in pregnancy, 124e-4  
 pyrimidine metabolism and, 431e-6  
 Fluoxetine  
 adverse effects of, 2710t, 2716  
 for cataplexy, 190  
 for depression, 64, 473, 2672, 2710t, 2716  
 drug interactions of, 34t, 40, 42, 42t  
 metabolism of, 34t, 40  
 for obsessive-compulsive disorder, 2714  
 for pain, 94  
 for panic disorder, 2709  
 pharmacology of, 2716, 2717  
 for Raynaud's phenomenon, 2164  
 Fluoxymesterone, 103e-15, 2371  
 Fluphenazine, 2722t  
 Flurazepam, 473e-10t, 2711t  
 Flushing  
 in acne rosacea, 352  
 in carcinoid syndrome, 564, 565  
 differential diagnosis of, 566  
 nicotinic acid therapy and, 96e-4  
 Flutamide, 103e-15, 335, 585  
 Fluvastatin, 2448t  
 Flvoxamine, 2710t, 2714  
 Fly bite, 2749–2750  
 Fly infestation, 2746–2747  
*FMRI* gene mutations, 336, 465e-1, 465e-2t  
 Foam cells, 291e-2, 365  
 Focal ataxia, 2627  
 Focal atrial tachycardia, 1477, 1478f, 1479, 1479f  
 Focal nodular hyperplasia, of liver, 553–554  
 Focal segmental glomerulosclerosis  
 clinical features of, 1835t, 1842  
 genetic considerations in, 1832  
 HIV-related, 1849  
 pathogenesis of, 1842, 1842f, 1842t  
 renal biopsy in, 62e-1f, 62e-2f, 1842  
 treatment of, 1842–1843  
 Focal seizures. *See* Seizure(s), focal  
 FODMAPs, 1968–1969, 1968t  
 Fogo salvagem, 371  
 Folate, 640  
 absorption of, 640–641  
 for alcohol-induced acidosis, 64e-9  
 cobalamin and, 641  
 deficiency of. *See* Folate deficiency  
 dietary sources of, 640  
 functions of, 96e-2f, 641, 641t, 642f  
 parenteral requirement for, 98e-5t  
 red cell, 648  
 reference values for, 2766t  
 requirement/recommended intake of, 95e-2t, 641  
 serum, 647–648